Showing 1791-1800 of 2007 results for "".
- Aaron Burton Named CEO at Scitonhttps://modernaesthetics.com/news/aaron-burton-named-ceo-at-sciton/2472888/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently o
- Molly Sims Named New SoME Skincare Brand Ambassadorhttps://modernaesthetics.com/news/molly-sims-named-new-some-skincare-brand-ambassador/2472887/Molly Sims is Brand Ambassador for Aesthetics Biomedical’s SoME Skincare That's All You, a patented personalized Platelet Rich Plasma (PRP) skincare for at-home use. SoME That's All You is combined with your PRP b
- FDA Sets November PDUFA Date for DaxibotulinumtoxinA from Revancehttps://modernaesthetics.com/news/fda-sets-november-pdufa-date-for-daxibotulinumtoxina-from-revance/2472880/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Candela Launches Exceed Medical Microneedling Systemhttps://modernaesthetics.com/news/candela-launches-exceed-medical-microneedling-system/2472878/Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM's medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- Cynosure News: Todd Tillemans Named New CEOhttps://modernaesthetics.com/news/cynosure-news-todd-tillemans-named-new-ceo/2472869/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- Credentials Over Cost: AAFPRS Issues Warning to Consumers about Discount Cosmetic Treatmentshttps://modernaesthetics.com/news/credentials-over-cost-aafprs-issues-warning-to-consumers-about-discount-cosmetic-treatments/2472867/When promoting your practice, remind potential patients about your credentials and why they must choose a doctor based on his/her training and experience and not simply the best price. The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) has issued a war
- Crown Laboratories Restructures after Acquisitionshttps://modernaesthetics.com/news/crown-laboratories-restructures-after-acquisitions/2472866/Crown Laboratories has restructured its commercial operations business units as it continues to elevate its new “Skin Science for Life” commitment. For the past two years, Crown says it has been dedicated to transforming its Northeast Tennessee operations into a global skinc
- Revance Enters Exclusive Distribution Deal with Teoxane SA for Dermal Fillershttps://modernaesthetics.com/news/revance-enters-exclusive-distribution-deal-with-teoxane-sa-for-dermal-fillers/2472863/With the signing of a new distribution agreement, Revance Therapeutics, Inc. is now the exclusive US commercialization partner of Teoxane SA for its dermal filler products. Revance has immediate and exclusive rights to commercialize Teoxane’s Resilient Hyaluronic Acid® (R
- Revian: USPTO Grants Patent for Biostimulatory Approachhttps://modernaesthetics.com/news/regina-uspto-grants-patent-for-biostimulatory-approach/2472862/The United States Patent and Trademark Office (USPTO) has awarded to Revian Inc. U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the use